https://www.selleckchem.com/pr....oducts/Enzastaurin.h
A clinically significant hearing improvement ( 10d was seen in 18 patients (58.1%) in the initial-protocol group and in 14 patients (41.9%) in the revised-protocol group. A comparison of the hearing outcomes between protocol groups revealed no statistically significant differences (p 0.05). These results indicate that a shorter injection interval does not lead to better hearing outcomes in ITS salvage treatment for ISSNHL. Moreover, fewer ITS injections may reduce costs, physical/mental stress of the patients and lower th
Gefällt mir
Kommentar
Teilen
